We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Vaccination with Receptor Protein Protects Mice against AD

By LabMedica International staff writers
Posted on 12 Sep 2018
A soluble version of a protein involved in the formation of toxic amyloid plaques was shown to prevent aggregation of amyloid beta (Abeta) and slow development of Alzheimer's disease (AD) in a mouse model.

The brains of Alzheimer's disease patients have been shown to express elevated levels of Toll-like receptors (TLRs), a family of proteins on the surface of immune cells that recognize molecules released by pathogens or damaged cells and then initiate an appropriate immune response. More...
Investigators at the University of Florida (Gainesville, USA) hypothesized that a decoy receptor strategy using the external domain of select TLRs could have therapeutic potential in AD.

To test this hypothesis, the investigators injected members of an AD mouse model with AAV (Adeno-associated virus) human TLR5 external domain (sTLR5) alone or fused to the human antibody fragment, IgG4 Fc (sTLR5Fc).

Results reported in the August 29, 2018, online edition of the Journal of Experimental Medicine revealed that immunization with soluble versions of TLR5 reduced the buildup of amyloid plaques in the brains of the Alzheimer's disease model mice. In vitro, these proteins protected neurons from being killed by accumulation of toxic amyloid plaques.

Senior author Dr. Todd E. Golde, professor of neuroscience at the University of Florida, said, "By directly interacting with beta-amyloid and attenuating beta-amyloid levels in mice, the soluble TLR5 decoy receptor represents a novel and potentially safe class of immunomodulatory agents for Alzheimer's disease."

Related Links:
University of Florida


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
New
Slide Scanner System
NanoZoomer S540MD
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.